Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Immunome, Inc. logo — Transformative Targeted Therapies

Immunome, Inc.

Transformative Targeted Therapies

Founded 2008 United States Bothell, United States 246 employees IPO Total: $1.02B Biopharma, Biotechnology +1

General Information

Company Name Immunome, Inc.
Founded Year 2008
Location United States Bothell, United States +1
Founders / Decision Makers
Team member Team member
Employees 246
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage IPO
Social

Get notified when Immunome, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Immunome, Inc. is demonstrating strong post-IPO momentum, securing substantial capital through recent private placements and planned future equity rounds totaling over $800M. This significant funding supports the continued advancement of its targeted oncology pipeline, highlighted by its planned presentation of new desmoid tumor data at ASCO26, underscoring its strategic focus on clinical development and market visibility.

Signal Types
Funding Clinical Development Event Participation
Strategic Labels
Clinical Advancement Capital Infusion Market Visibility
Next Move: Data Release
·
Impact: 9/10
·
Ideal For: Biotech Public Equity Funds — Clinical Stage Oncology

About Immunome, Inc.

Immunome, Inc. is a biotechnology company focused on developing antibody-based therapeutics by unlocking the human memory B cell response. Founded in 2008 and headquartered in the United States, the company has a growing pipeline of cancer immunotherapies fueled by the human immune system. Immunome's proprietary technology platform leverages the "most highly educated" immune systems from patients to simultaneously discover novel antigens and patient-derived native antibodies. This unique approach enables the identification of specific and high-affinity antibodies with significant therapeutic potential to revolutionize cancer treatment. The company recently received a notable $230.00M Post-IPO Equity investment on 13 February 2024. With its innovative approach and promising pipeline, Immunome is poised to make a substantial impact in the Biopharma, Biotechnology, and Pharmaceutical industries.

Taxonomy: antibody-based therapeutics, immunotherapy, cancer, immune system, discovery engine, antigens, high-content screening, therapeutic potential

Funding Rounds & Investors (18)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Equity •••••• - 01 Dec 2025
Post Ipo Equity •••••• - 01 Jan 2025
Post Ipo Equity •••••• - 01 Feb 2024
Private Placement Vc •••••• 6
Investor Investor Investor Investor Investor
•••• •••• 		01 Oct 2023
Grant •••••• - 01 Jul 2021

View All 18 Funding Rounds

Immunome, Inc. Alternatives & Competitors

Immunome, Inc. vs
Molecular Templates
Molecular Templates United States

Engineering the Next Generation of Therapeutics

Post Ipo Equity
26 employees
Biotechnology, Health Care
Compare Immunome, Inc. vs Molecular Templates
Immunome, Inc. vs
MimiVax, Inc.
MimiVax, Inc. United States

Disrupting Cancer with Immunotherapy

Series Unknown
3 employees
Biopharma, Biotechnology
Compare Immunome, Inc. vs MimiVax, Inc.
Immunome, Inc. vs
Rubius Therapeutics
Rubius Therapeutics United States

Red blood cells are no longer just for carrying oxygen. At Rubius Therapeutics, we are transforming...

IPO
18 employees
Biotechnology
Compare Immunome, Inc. vs Rubius Therapeutics

FAQ About Immunome, Inc.

Transformative Targeted Therapies
Immunome, Inc. was founded in 2008.
Immunome, Inc. is headquartered in Bothell, United States.
Immunome, Inc. operates in the following industries: Biopharma, Biotechnology, Pharmaceutical.
Immunome, Inc. has approximately 246 employees.
Immunome, Inc. has completed 18 funding rounds, raising a total of $1.02B. The latest funding stage is IPO.
Top alternatives and competitors to Immunome, Inc. include Molecular Templates, MimiVax, Inc., Rubius Therapeutics, Tagworks Pharmaceuticals, GO Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Immunome, Inc. and Molecular Templates are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Immunome, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy